PridCor Therapeutics

Executive Summary

PridCor Therapeutics is a private biotech company founded in 2021, focused on addressing the significant unmet medical need in post-viral and chronic syndromes, including Long COVID, fibromyalgia, ME/CFS, and IBS. The company's innovative approach combines repurposed drugs in novel combinations with proprietary medical devices to target underlying viral reactivation and inflammation. Currently in Phase 1 development, PridCor is advancing its lead candidates through early clinical trials, with the potential to provide novel treatment options for millions of patients suffering from these debilitating conditions that currently lack approved therapies. Its dual strategy of drug-device combination offers a differentiated mechanism of action and potential for synergistic efficacy.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 clinical data readout for lead candidate65% success
• Q2 2026FDA pre-IND or Type C meeting for next program70% success
• Q3 2026Strategic partnership for device component50% success